Publicacions (104) Publicacions de María D. Odero

2023

  1. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

    Blood, Vol. 141, Núm. 9, pp. 1047-1059

  2. Regulation and role of the PP2A-B56 holoenzyme family in cancer

    Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1878, Núm. 5

  3. Set Protein Is Involved in FLT3 Membrane Trafficking

    Cancers, Vol. 15, Núm. 8

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

  2. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

2020

  1. A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia

    Blood Cancer Journal, Vol. 10, Núm. 1

  2. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity

    Cancer Letters, Vol. 468, pp. 1-13

  3. Data mining analysis of the PP2A cell cycle axis in mesothelioma patients

    Journal of Cellular Physiology, Vol. 235, Núm. 6, pp. 5284-5292

  4. The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias

    Cells, Vol. 9, Núm. 3

2019

  1. Comment on "pP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia"

    Science Translational Medicine, Vol. 11, Núm. 501

2018

  1. Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib

    Oncotarget, Vol. 9, Núm. 47, pp. 28474-28485

2017

  1. MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia

    Oncotarget, Vol. 8, Núm. 33, pp. 53989-54003

  2. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

    Oncogene, Vol. 36, Núm. 19, pp. 2737-2749

  3. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells

    Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, Vol. 1860, Núm. 6, pp. 721-729

2016

  1. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia

    Oncotarget, Vol. 7, Núm. 51, pp. 84214-84227

  2. Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia

    Frontiers in Oncology, Vol. 6, Núm. APR

2015

  1. CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

    Haematologica

  2. Estudio de la proteína fosfatasa PP2A como diana terapéutica en leucemia mieloide aguda (78/2012)

    Anales del sistema sanitario de Navarra, Vol. 38, Núm. 2, pp. 358-359

  3. GATA2 germline mutations impair GATA2 transcription, causing haploinsufficiency: Functional analysis of the p.Arg396Gln mutation

    Journal of Immunology, Vol. 194, Núm. 5, pp. 2190-2198

  4. Lipid nanosystems enhance the bioavailability and the therapeutic efficacy of FTY720 in acute myeloid leukemia

    Journal of Biomedical Nanotechnology, Vol. 11, Núm. 4, pp. 691-701